Complex I Deficiency
Complex I Deficiency - Related Videos
01:30
Capital Deficiency in Liquidation: I
0 Views •
2026
During the liquidation of a partnership, a capital deficiency occurs when a partner’s capital account becomes negative after accounting for allocated losses and the payment of liabilities. Resolving such deficiencies is a critical step before the remaining assets can be distributed. However, complications arise when a partner is unable or unwilling to contribute additional funds to eliminate their deficiency.In cases where a partner cannot satisfy their capital deficiency, the loss must be...
01:25
Capital Deficiency in Liquidation: II
0 Views •
2026
A capital deficiency occurs when a partner's capital account has a debit balance during partnership liquidation. It may result from operating losses, excessive drawings, or losses from the sale of partnership assets. During liquidation, noncash assets are sold, liabilities are paid, gains or losses are allocated to the partners, and the remaining cash is distributed based on the partners' capital balances.Example: Ace Company decides to liquidate because it is nearing bankruptcy. Noncash assets...
01:30
No Capital Deficiency in Liquidation
0 Views •
2026
In accounting, liquidation without capital deficiency is a structured process that enables a partnership to dissolve equitably when partners possess sufficient capital to cover all liabilities and allocated losses. This condition ensures that no partner is required to contribute additional funds to the partnership, streamlining the dissolution procedure.The liquidation process begins with conversion of noncash assets into cash. When these assets are sold, any difference between the sale price...
04:55
A Simple Mechanical Procedure to Create Limbal Stem Cell Deficiency in Mouse
0 Views •
Cited by 11 •
2016
The following article provides an easy, reproducible technique to effectively create a sustainable mouse model of limbal stem cell deficiency (LSCD). This animal model is useful in testing and comparing the efficacy of treatments for limbal stem cell diseases.
28:15
Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
0 Views •
Cited by 22 •
2010
Reduced/absent expression of Pms2 and/or ERCC1 in entire crypts is a frequent event within 10 cm on each side of colonic adenocarcinomas, likely the basis of a field defect with high mutability and progression to cancer. Deficiency in Ku86 or CcOI is much less frequent in these field defects.
FAQs
When Complex I activity falls, electron transfer from NADH to ubiquinone becomes less effective, and proton movement across the inner mitochondrial membrane is reduced. The resulting weaker electrochemical gradient gives ATP synthase less driving force for ATP production. This links a defect in one respiratory-chain complex to a broader cellular energy shortage, rather than an isolated change in electron handling.
Brain, heart, muscle, and other organs can be affected because tissues with high energy demands are especially vulnerable to reduced mitochondrial energy production. This pattern provides important biological context when studying Complex I deficiency. It also explains why the disorder can appear across multiple organ systems rather than remaining confined to one anatomical site.
Complex I deficiency begins upstream of ATP synthesis: the primary problem is inefficient activity of the first respiratory-chain enzyme, while the downstream consequence is a reduced proton gradient. This distinction helps investigators interpret mitochondrial studies as pathway-level evidence and determine how an early electron-transfer defect affects the energy-generating system as a whole.
Alongside reduced energy production, impaired activity may increase reactive oxygen species, creating another consequence of respiratory-chain dysfunction. Considering this possibility prevents interpretation from focusing on ATP shortage alone. It keeps attention on both electron-transfer performance and the altered oxidative balance that may accompany mitochondrial respiratory-chain impairment.
Establishing a diagnosis generally combines biochemical assays, genetic testing, and mitochondrial studies rather than depending on a single type of evidence. These approaches address complementary aspects of the disorder: biochemical and mitochondrial investigations relate to respiratory-chain function, while genetic testing adds genetic information. Together, the findings can support diagnosis and more informative disease classification.
Genetic testing and mitochondrial studies contribute different kinds of evidence. Genetic testing can help connect the disorder to an underlying genetic finding, whereas mitochondrial studies examine respiratory-chain function in its cellular setting. Used together with biochemical assays, they can strengthen diagnosis and improve disease classification while supplying information relevant to research on treatment strategies.